Toth Financial Advisory Corp Acquires 180 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Toth Financial Advisory Corp boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,070 shares of the biotechnology company’s stock after purchasing an additional 180 shares during the period. Toth Financial Advisory Corp’s holdings in United Therapeutics were worth $1,083,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of UTHR. Benjamin F. Edwards & Company Inc. raised its holdings in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 42 shares in the last quarter. Evergreen Capital Management LLC bought a new position in United Therapeutics during the second quarter valued at about $375,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of United Therapeutics by 52.7% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 8,565 shares of the biotechnology company’s stock valued at $2,728,000 after purchasing an additional 2,955 shares during the period. Toronto Dominion Bank raised its position in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares during the period. Finally, AXA S.A. raised its position in shares of United Therapeutics by 14.4% in the second quarter. AXA S.A. now owns 65,040 shares of the biotechnology company’s stock valued at $20,718,000 after purchasing an additional 8,208 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $378.36.

Insider Activity

In other news, Director Nilda Mesa sold 224 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the sale, the director now owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 146,848 shares of company stock worth $55,165,099. Company insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $370.83 on Friday. The firm has a market capitalization of $16.56 billion, a PE ratio of 16.29, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The company’s fifty day moving average price is $365.19 and its two-hundred day moving average price is $355.61. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the firm posted $5.38 EPS. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. Analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.